ARIH1-modified immune cells and uses thereof
Modified immune cells with reduced ARIH1 and BCL11B expression, engineered for enhanced degranulation and cytotoxicity, address persistence and rejection issues, improving therapeutic efficacy in cancer treatment.
WO2026021484A1 Publication Date: 2026-01-29PEKING UNIV +1
3 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/110118
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-23
- Filing Date
- 2025-07-23
- Publication Date
- 2026-01-29
AI Technical Summary
Technical Problem
Allogeneic immune cells, such as CAR-T and CAR-NK cells, face challenges including poor persistence due to host immune rejection, activation-induced cell death, and graft-versus-host disease, limiting their therapeutic effectiveness in cancer treatment.
Method used
Modified immune cells with reduced expression and/or function of ARIH1 and optionally BCL11B proteins, engineered with receptors like CAR, are developed using gene editing techniques like CRISPR/Cas9, enhancing degranulation, cytotoxicity, and persistence.
Benefits of technology
The modified immune cells exhibit enhanced degranulation, cytotoxicity, and persistence, reducing host rejection and graft-versus-host disease, making them more effective in treating cancers and other conditions.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided relates to immune cells (e.g., T cells such as γδ T cells) modified to have no or reduced expression and / or function of Ariadne homolog 1 (ARIH1) and further optionally BCL11B, uses thereof (e.g., for treating glioblastoma), and methods of generating thereof. Also provided are methods of modifying γδ T cells using pseudotyped lentiviruses (e.g., BaEV-Rless glycoprotein or BaEV-TR glycoprotein pseudotyped lentiviruses).
Need to check novelty before this filing date? Find Prior Art